PDF DatasheetAntibody (Suitable for clinical applications)
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:50-1:100 |
| Pretreatment | EDTA Buffer pH 8.0 |
| Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Cytokeratin 19 Information for Pathologists
Summary:
Molecular weight is 40 kDa (smallest cytokeratin). Often coexpressed with CK7. Present in both simple and complex epithelium. Involved in the organization of myofibers; links contractile apparatus to dystrophin at costameres of striated muscle (also CK8, Mol Biol Cell 2005;16:4280). Polymorphisms of CK19 pseudogene are associated with primary biliary cirrhosis (Hepatol Res 2003;25:281).
Common Uses By Pathologists:
Bladder: possible urine screening test for bladder carcinoma (J Egypt Natl Canc Inst 2006;18:82). Bone / soft tissue: distinguish chordoma (CK19+) from parachordoma (CK19-, Ann Diagn Pathol 1997;1:3). Breast: presence of CK19+ peripheral blood tumor cells or CK19+ fragments is a poor prognostic factor for breast cancer (predicts CNS relapse, Breast Cancer Res 2006;8:R36). Liver: distinguish hepatocellular carcinoma (CK19-) from either hepatoid adenocarcinoma metastatic to liver (CK19+, Am J Surg Pathol 2003;27:1302) or cholangiocarcinoma (CK19+, J Gastrointestin Liver Dis 2006;15:9, Am J Clin Pathol 2006;125:519). Liver: poor prognostic factor in hepatocellular carcinoma (Histopathology 2006;49:138, Cancer Sci 2003;94:851).
| Cytokeratin 19 General Information | |
|---|---|
| Alternate Names | |
| Molecular Weight | |
| 44.1 kDa | |
| Chromosomal Location | |
| q21.2 [chr: 17] [chr_start: 41523617] [chr_end: 41528308] [strand: -1] | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | KRT19 |
| Entrez Gene ID | 3880 |
| RefSeq Protein Accession(s) | NP_002267 |
| RefSeq mRNA Accession(s) | ; NM_002276 |
| RefSeq Genomic Accession(s) | NC_000017; NG_012285 |
| UniProt ID(s) | P08727 |
| PharmGKB ID(s) | PA30225 |
| KEGG Gene ID(s) | hsa:3880 |
| General Description of Cytokeratin 19 . | |
| This antibody is specific to a 40 kDa protein, cytokeratin 19. Its epitope maps between amino acids 312-335. This antibody reacts with MCF-7 cells, which are known to contain cytokeratin 19. | |
There are no reviews yet.